Disease Landscape and Forecast Insights

Alongside putative disease-modifying therapies, the late-phase pipeline in Alzheimer’s disease (AD) features several therapies for the treatment of behavioral symptoms in AD. Symptoms such as…

With the launch of four adalimumab biosimilars into the European market in October 2018—Amgevita (Amgen), Imraldi (Biogen), Hulio (Mylan), and Hyrimoz (Sandoz)—competition within the already…

Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its launch comes years after that of Pfizer’s Jak inhibitor, Xeljanz (…

As the term implies, levodopa-induced dyskinesia (LID) is a complication of chronic use of levodopa, the gold standard of Parkinson’s disease (PD) treatment. Surveyed neurologists estimate that…

The wet age-related macular degeneration (AMD) market in the United States is unique in that it is dominated by Genentech’s Avastin, an oncology drug that is used off-label to treat wet AMD,…

MARKET OUTLOOK Despite similarities between adult psoriasis and pediatric psoriasis, pediatric psoriasis presents a challenge for patients seeking effective long-term therapy. Thetreatments…

MARKET OUTLOOK Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are gaining traction in the COPD market, and both LAMAs and LABA/…

MARKET OUTLOOK Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The…

For the estimated 5 million people in the United States with AF, several treatment approaches are used, each with a wide range of pharmacological options. The established guidelines recommend the…

Most uveitis-related vision loss is the result of chronic inflammation of the posterior segment of the eye (i.e., intermediate, posterior, and panuveitis). Although noninfectious anterior uveitis…

Dupixent (Sanofi/Regeneron), a first-in-class biologic that inhibits IL-4/IL-13 signaling, was approved for the treatment of eosinophilic asthma and oral-corticosteroid-dependent asthma in October…

Market Outlook Pfizer’s Xeljanz is the first-in-class Jak inhibitor approved for ulcerative colitis (UC) in the United States and the first targeted oral therapy to launch for moderate to…